Home A review of pharmacogenetic studies in the Bangladeshi population
Article
Licensed
Unlicensed Requires Authentication

A review of pharmacogenetic studies in the Bangladeshi population

  • Md. Shaki Mostaid , Md. Abdul Aziz ORCID logo , Jeba Atkia Maisha , Mohammad Safiqul Islam and Abdullah Al Maruf ORCID logo EMAIL logo
Published/Copyright: March 1, 2023
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Drug Metabolism and Personalized Therapy
From the journal Drug Metabolism and Personalized Therapy Volume 38 Issue 2

Abstract

Pharmacogenetics (PGx)-guided prescribing is an evidence-based precision medicine strategy. Although the past two decades have reported significant advancements in both the quality and quantity of PGx research studies, they are seldom done in developing countries like Bangladesh. This review identified and summarized PGx studies conducted in the Bangladeshi population by searching PubMed and Google Scholar. Additionally, a quality evaluation of the identified studies was also carried out. Eleven PGx studies were identified that looked at the effects of genetic variants on blood thinners (CYP2C9, VKORC1, and ITGB3), cancer drugs (TPMT, MTHFR, DPYD, ERCC1, GSTP1, XPC, XRCC1, TP53, XPD, and ABCC4), statins (COQ2, CYP2D6, and CYP3A5), and prednisolone (ABCB1, CYP3A5, and NR3C1) in the Bangladeshi population. Most studies were of low to moderate quality. Although the identified studies demonstrated the potential for PGx testing, the limited PGx literature in the Bangladeshi population poses a significant challenge in the widespread implementation of PGx testing in Bangladesh.

Keywords: Bangladesh; implementation; pharmacogenetics; precision medicine
Corresponding author: Abdullah Al Maruf, PhD, M.Pharm, Associate Member and Adjunct Assistant Professor, The Mathison Centre for Mental Health Research & Education, Department of Psychiatry, Cumming School of Medicine, University of Calgary, 3280 Hospital Dr. NW, Calgary, Alberta T2N 4Z6, Canada, Phone: + 1 4032106464, E-mail:
Md. Shaki Mostaid and Md. Abdul Aziz contributed equally to this work.

  1. Research funding: None declared.

  2. Author contributions: Conceptualization, M.A.A. and A.M.; methodology, M.S.M. and M.A.A.; resources, M.S.M. and M.A.A.; data curation, M.S.M., M.A.A. and J.A.M.; writing—original draft preparation, M.S.M. and M.A.A.; writing—review and editing, M.S.M., M.A.A., J.A.M., M.S.I., and A.M. All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Authors state no conflicts of interest.

  4. Informed consent: Not applicable.

  5. Ethical approval: Not applicable.

  6. Data availability: All data generated/analyzed during this study are included in this article.

References

1. Lazarou, J, Pomeranz, BH, Corey, PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200–5. https://doi.org/10.1001/jama.279.15.1200.Search in Google Scholar PubMed

2. Hohl, CM, Nosyk, B, Kuramoto, L, Zed, PJ, Brubacher, JR, Abu-Laban, RB, et al.. Outcomes of emergency department patients presenting with adverse drug events. Ann Emerg Med 2011;58:270–9.e4. https://doi.org/10.1016/j.annemergmed.2011.01.003.Search in Google Scholar PubMed

3. Relling, MV, Evans, WE. Pharmacogenomics in the clinic. Nature 2015;526:343–50. https://doi.org/10.1038/nature15817.Search in Google Scholar PubMed PubMed Central

4. Hockings, JK, Pasternak, AL, Erwin, AL, Mason, NT, Eng, C, Hicks, JK. Pharmacogenomics: an evolving clinical tool for precision medicine. Cleve Clin J Med 2020;87:91–9. https://doi.org/10.3949/ccjm.87a.19073.Search in Google Scholar PubMed

5. Mostafa, S, Kirkpatrick, CMJ, Byron, K, Sheffield, L. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes. J Neural Transm 2019;126:5–18. https://doi.org/10.1007/s00702-018-1922-0.Search in Google Scholar PubMed

6. Bush, WS, Crosslin, DR, Owusu-Obeng, A, Wallace, J, Almoguera, B, Basford, MA, et al.. Genetic variation among 82 pharmacogenes: the PGRNseq data from the eMERGE network. Clin Pharmacol Ther 2016;100:160–9. https://doi.org/10.1002/cpt.350.Search in Google Scholar PubMed PubMed Central

7. Van Driest, SL, Shi, Y, Bowton, EA, Schildcrout, JS, Peterson, JF, Pulley, J, et al.. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. Clin Pharmacol Ther 2014;95:423–31. https://doi.org/10.1038/clpt.2013.229.Search in Google Scholar PubMed PubMed Central

8. McInnes, G, Lavertu, A, Sangkuhl, K, Klein, TE, Whirl-Carrillo, M, Altman, RB. Pharmacogenetics at scale: an analysis of the UK biobank. Clin Pharmacol Ther 2021;109:1528–37. https://doi.org/10.1002/cpt.2122.Search in Google Scholar PubMed PubMed Central

9. Ramsey, LB, Ong, HH, Schildcrout, JS, Shi, Y, Tang, LA, Hicks, JK, et al.. Prescribing prevalence of medications with potential genotype-guided dosing in pediatric patients. JAMA Netw Open 2020;3:e2029411. https://doi.org/10.1001/jamanetworkopen.2020.29411.Search in Google Scholar PubMed PubMed Central

10. Luzum, JA, Petry, N, Taylor, AK, Van Driest, SL, Dunnenberger, HM, Cavallari, LH. Moving pharmacogenetics into practice: it’s all about the evidence. Clin Pharmacol Ther 2021;110:649–61. https://doi.org/10.1002/cpt.2327.Search in Google Scholar PubMed PubMed Central

11. Swen, JJ, Nijenhuis, M, de Boer, A, Grandia, L, Maitland-van der Zee, AH, Mulder, H, et al.. Pharmacogenetics: from bench to byte—an update of guidelines. Clin Pharmacol Ther 2011;89:662–73. https://doi.org/10.1038/clpt.2011.34.Search in Google Scholar PubMed

12. Relling, MV, Klein, TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the pharmacogenomics research network. Clin Pharmacol Ther 2011;89:464–7. https://doi.org/10.1038/clpt.2010.279.Search in Google Scholar PubMed PubMed Central

13. Ross, CJ, Visscher, H, Sistonen, J, Brunham, LR, Pussegoda, K, Loo, TT, et al.. The Canadian pharmacogenomics network for drug safety: a model for safety pharmacology. Thyroid 2010;20:681–7. https://doi.org/10.1089/thy.2010.1642.Search in Google Scholar PubMed

14. Picard, N, Boyer, JC, Etienne-Grimaldi, MC, Barin-Le Guellec, C, Thomas, F, Loriot, MA, et al.. Pharmacogenetics-based personalized therapy: levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx). Therapie 2017;72:185–92. https://doi.org/10.1016/j.therap.2016.09.014.Search in Google Scholar PubMed

15. García-Alfonso, P, Saiz-Rodríguez, M, Mondéjar, R, Salazar, J, Páez, D, Borobia, AM, et al.. Consensus of experts from the spanish pharmacogenetics and pharmacogenomics society and the spanish society of medical oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines. Clin Transl Oncol 2022;24:483–94. https://doi.org/10.1007/s12094-021-02708-4.Search in Google Scholar PubMed PubMed Central

16. The Clinical Pharmacogenetics Implementation Consortium. Implementation. Available from: https://cpicpgx.org/implementation [Accessed 29 Jun 2022].Search in Google Scholar

17. Tata, EB, Ambele, MA, Pepper, MS. Barriers to implementing clinical pharmacogenetics testing in sub-saharan africa. A critical review. Pharmaceutics 2020;12:809. https://doi.org/10.3390/pharmaceutics12090809.Search in Google Scholar PubMed PubMed Central

18. Maruf, AA, Fan, M, Arnold, PD, Müller, DJ, Aitchison, KJ, Bousman, CA. Pharmacogenetic testing options relevant to psychiatry in Canada: options de tests pharmacogénétiques pertinents en psychiatrie au Canada. Can J Psychiatr 2020;65:521–30. https://doi.org/10.1177/0706743720904820.Search in Google Scholar PubMed PubMed Central

19. Haga, SB, Kantor, A. Horizon scan of clinical laboratories offering pharmacogenetic testing. Health Aff 2018;37:717–23. https://doi.org/10.1377/hlthaff.2017.1564.Search in Google Scholar PubMed PubMed Central

20. Jorgensen, AL, Williamson, PR. Methodological quality of pharmacogenetic studies: issues of concern. Stat Med 2008;27:6547–69. https://doi.org/10.1002/sim.3420.Search in Google Scholar PubMed

21. Bin Sayeed, MS, Apu, MNS, Munir, MT, Ahmed, MU, Islam, MS, Haq, MM, et al.. Prevalence of CYP2C19 alleles, pharmacokinetic and pharmacodynamic variation of clopidogrel and prasugrel in Bangladeshi population. Clin Exp Pharmacol Physiol 2015;42:451–7. https://doi.org/10.1111/1440-1681.12390.Search in Google Scholar PubMed

22. Bushra, MU, Rivu, SF, Sifat, AE, Nahid, NA, Ahmed, MU, Al-Mamun, MMA, et al.. Genetic polymorphisms of GSTP1, XRCC1, XPC and ERCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer patients of Bangladesh. Mol Biol Rep 2020;47:7073–82. https://doi.org/10.1007/s11033-020-05771-2.Search in Google Scholar PubMed

23. Chowdhury, ZS, Shahjin, F, Akter, F, Ahmed, M, Islam, MS, Bin Sayeed, MS, et al.. Effect of VKORC1 and CYP2C9 polymorphisms on warfarin dose requirement in Bangladeshi population. Pak J Pharm Sci 2017;30:341–6.Search in Google Scholar

24. Chowdhury, FA, Baker, SMEA, Islam, MS, Nahid, NA, Mamun, MAA, Islam, MR, et al.. Association between variants of COQ2 and TNF-α genes and statin-induced toxicities in Bangladeshi hyperlipidemic patients. Drugs Ther Perspect 2019;35:621–6. https://doi.org/10.1007/s40267-019-00677-x.Search in Google Scholar

25. Islam, MS, Islam, MS, Parvin, S, Ahmed, MU, Bin Sayeed, MS, Uddin, MM, et al.. Effect of GSTP1 and ABCC4 gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-5-fluorouracil-based chemotherapy in Bangladeshi breast cancer patients. Tumor Biol 2015;36:5451–7. https://doi.org/10.1007/s13277-015-3211-y.Search in Google Scholar PubMed

26. Maruf, AA, Ahmed, MU, Yasmin, H, Ullah, MA, Azad, MA, Daly, AK, et al.. Genotypes and phenotypes of CYP3A in Bangladeshi population. Clin Chim Acta 2011;412:531–6. https://doi.org/10.1016/j.cca.2010.11.031.Search in Google Scholar PubMed

27. Nahid, NA, Apu, MNH, Islam, MR, Shabnaz, S, Chowdhury, SM, Ahmed, MU, et al.. DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer. Cancer Chemother Pharmacol 2018;81:119–29. https://doi.org/10.1007/s00280-017-3478-3.Search in Google Scholar PubMed

28. Nairuz, T, Bushra, YU, Kabir, Y. Effect of XPD and TP53 gene polymorphisms on the risk of platinum-based chemotherapy induced toxicity in Bangladeshi lung cancer patients. Asian Pac J Cancer Prev APJCP 2021;22:3809–15. https://doi.org/10.31557/apjcp.2021.22.12.3809.Search in Google Scholar

29. Parvin, MN, Aziz, MA, Rabbi, SNI, Al-Mamun, MMA, Hanif, M, Islam, MS, et al.. Assessment of the link of ABCB1 and NR3C1 gene polymorphisms with the prednisolone resistance in pediatric nephrotic syndrome patients of Bangladesh: a genotype and haplotype approach. J Adv Res 2021;33:141–51. https://doi.org/10.1016/j.jare.2021.02.001.Search in Google Scholar PubMed PubMed Central

30. Rashid, MMU, Ahmed, I, Islam, MA, Tasnim, T, Nahid, NA, Apu, MNH, et al.. Influence of TPMT polymorphisms on azathioprine-induced myelosuppression in Bangladeshi patients with systemic lupus erythematosus. Drugs Ther Perspect 2020;36:202–7. https://doi.org/10.1007/s40267-020-00716-y.Search in Google Scholar

31. Zahra, FT, Nahid, NA, Islam, MR, Al-Mamun, MMA, Apu, MNH, Nahar, Z, et al.. Pharmacogenetic variants in MTHFR gene are significant predictors of methotrexate toxicities in Bangladeshi patients with acute lymphoblastic leukemia. Clin Lymphoma, Myeloma & Leukemia 2020;20:e58–65. https://doi.org/10.1016/j.clml.2019.11.020.Search in Google Scholar PubMed

32. Islam, MR, Nova, TT, Momenuzzaman, N, Rabbi, SNI, Jahan, I, Binder, T, et al.. Prevalence of CYP2C19 and ITGB3 polymorphisms among Bangladeshi patients who underwent percutaneous coronary intervention. SAGE Open Med 2021;9:20503121211042209. https://doi.org/10.1177/20503121211042209.Search in Google Scholar PubMed PubMed Central

33. Ahsan, H, Chen, Y, Kibriya, MG, Islam, MN, Slavkovich, VN, Graziano, JH, et al.. Susceptibility to Arsenic-induced hyperkeratosis and oxidative stress genes myeloperoxidase and catalase. Cancer Lett 2003;201:57–65. https://doi.org/10.1016/s0304-3835(03)00471-3.Search in Google Scholar PubMed

34. Akther, J, Ebihara, A, Nakagawa, T, Islam, LN, Suzuki, F, Hosen, MI, et al.. Analyses of genetic variations of Glutathione S-transferase Mu1 and Theta1 genes in Bangladeshi Tannery workers and healthy controls. BioMed Res Int 2016;2016:6973057. https://doi.org/10.1155/2016/6973057.Search in Google Scholar PubMed PubMed Central

35. Ali, ME, Ahmed, MU, Alam, S, Rahman, MH. HLA-A, -B and -DRB1 allele frequencies in the Bangladeshi population. Tissue Antigens 2008;72:115–9. https://doi.org/10.1111/j.1399-0039.2008.01079.x.Search in Google Scholar PubMed

36. Aziz, R, Shariar, S, Khan, A, Akhteruzzaman, S, Sajib, AA. Multiplex allele-specific PCR to determine genotypes at statin metabolizing SNP loci- rs1135840 and rs776746. J Appl Biol Sci 2019;13:96–102.Search in Google Scholar

37. Hasan, MM, Hosen, MB, Rahman, MM, Howlader, MZH, Kabir, Y. Association of ATP binding cassette transporter 1 (ABCA 1) gene polymorphism with type 2 diabetes mellitus (T2DM) in Bangladeshi population. Gene 2019;688:151–4. https://doi.org/10.1016/j.gene.2018.12.003.Search in Google Scholar PubMed

38. Hosen, MB, Islam, J, Salam, MA, Islam, MF, Hawlader, MZ, Kabir, Y. N-acetyltransferase 2 gene polymorphism as a biomarker for susceptibility to bladder cancer in Bangladeshi population. Asia Pac J Clin Oncol 2015;11:78–84. https://doi.org/10.1111/ajco.12291.Search in Google Scholar PubMed

39. Islam, MS, Ahmed, MU, Sayeed, MS, Maruf, AA, Mostofa, AG, Hussain, SM, et al.. Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the Bangladeshi population. Clin Chim Acta 2013;416:11–9. https://doi.org/10.1016/j.cca.2012.11.011.Search in Google Scholar PubMed

40. Islam, T, Rahman, MS, Paul, N, Akhteruzzaman, S, Sajib, AA. Allele-specific detection of SLC22A2 rs316019 variants associated with metformin disposition through the kidney. Int J Diabetes Metabol 2018;21:22–8. https://doi.org/10.1159/000493584.Search in Google Scholar

41. Jahan, I, Ahammad, RU, Khalid, MM, Rahman, MI, Hayat, S, Islam, B, et al.. Toll-like receptor-4 299Gly allele is associated with Guillain-Barré syndrome in Bangladesh. Ann Clin Transl Neurol 2019;6:708–15. https://doi.org/10.1002/acn3.744.Search in Google Scholar PubMed PubMed Central

42. Khan, SF, Akter, M, Shahriar, S, Hossain, MA, Sajib, AA. MTHFR rs1801133 polymorphism in Bangladeshi population – its prevalence and detection. Asia Pac J Mol Biol 2020;28:94–101. https://doi.org/10.35118/apjmbb.2020.028.4.08.Search in Google Scholar

43. McCarty, KM, Chen, YC, Quamruzzaman, Q, Rahman, M, Mahiuddin, G, Hsueh, YM, et al.. Arsenic methylation, GSTT1, GSTM1, GSTP1 polymorphisms, and skin lesions. Environ Health Perspect 2007;115:341–5. https://doi.org/10.1289/ehp.9152.Search in Google Scholar PubMed PubMed Central

44. Montazid, MS, Sajib, AA, Hasan, KN, Khaleque, MA, Rahman, M, Sufian, A, et al.. Multiplex allele-specific detection of clinically important CYP2C19 variants associated with clopidogrel metabolism in a Bangladeshi population sample. Meta Gene 2021;27:100830. https://doi.org/10.1016/j.mgene.2020.100830.Search in Google Scholar

45. Ng, CS, Hasnat, A, Maruf, AA, Ahmed, MU, Pirmohamed, M, Day, CP, et al.. N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group. Eur J Clin Pharmacol 2014;70:1079–86. https://doi.org/10.1007/s00228-014-1703-0.Search in Google Scholar PubMed

46. Sonia, JA, Kabir, T, Islam, MMT, Kabir, Y. Catechol-O-methyltransferase and dopamine receptor D4 gene variants: possible association with substance abuse in Bangladeshi male. PLoS One 2021;16:e0246462. https://doi.org/10.1371/journal.pone.0246462.Search in Google Scholar PubMed PubMed Central

47. Tasnim, T, Al-Mamun, MMA, Nahid, NA, Islam, MR, Apu, MNH, Bushra, MU, et al.. Genetic variants of SULT1A1 and XRCC1 genes and risk of lung cancer in Bangladeshi population. Tumour Biol 2017;39:1010428317729270. https://doi.org/10.1177/1010428317729270.Search in Google Scholar PubMed

48. Huddart, R, Fohner, AE, Whirl-Carrillo, M, Wojcik, GL, Gignoux, CR, Popejoy, AB, et al.. Standardized biogeographic grouping system for annotating populations in pharmacogenetic research. Clin Pharmacol Ther 2019;105:1256–62. https://doi.org/10.1002/cpt.1322.Search in Google Scholar PubMed PubMed Central

49. Babu, G, Islam, SB, Khan, MA. A review on the genetic polymorphisms and susceptibility of cancer patients in Bangladesh. Mol Biol Rep 2022;49:6725–39. https://doi.org/10.1007/s11033-022-07282-8.Search in Google Scholar PubMed

50. Maruf, AA, Ahmed, MU, Azad, MA, Ahmed, M, Hasnat, A. CYP3A genotypes in Bangladeshi tuberculosis patients. Bangladesh Med Res Counc Bull 2012;38:1–5. https://doi.org/10.3329/bmrcb.v38i1.6978.Search in Google Scholar PubMed

51. Aka, TD, Saha, U, Shati, SA, Aziz, MA, Begum, M, Hussain, MS, et al.. Risk of type 2 diabetes mellitus and cardiovascular complications in KCNJ11, HHEX and SLC30A8 genetic polymorphisms carriers: a case-control study. Heliyon 2021;7:e08376. https://doi.org/10.1016/j.heliyon.2021.e08376.Search in Google Scholar PubMed PubMed Central

52. Chan, MY, Tan, K, Tan, HC, Huan, PT, Li, B, Phua, QH, et al.. CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects. Pharmacogenomics 2012;13:533–42. https://doi.org/10.2217/pgs.12.24.Search in Google Scholar PubMed

53. Eissa, DS, Ahmed, TM. C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: effect on methotrexate-related toxicity in adult acute lymphoblastic leukaemia. Blood Coagul Fibrinolysis 2013;24:181–8. https://doi.org/10.1097/mbc.0b013e32835b249d.Search in Google Scholar PubMed

54. Ayad, MW, El Naggar, AA, El Naggar, M. MTHFR C677T polymorphism: association with lymphoid neoplasm and effect on methotrexate therapy. Eur J Haematol 2014;93:63–9. https://doi.org/10.1111/ejh.12302.Search in Google Scholar PubMed

55. Kishi, S, Cheng, C, French, D, Pei, D, Das, S, Cook, EH, et al.. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 2007;109:4151–7. https://doi.org/10.1182/blood-2006-10-054528.Search in Google Scholar PubMed PubMed Central

56. Wu, NC, Su, SM, Lin, TJ, Chin, J, Hou, CF, Yang, JY, et al.. Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and fluorouracil-based treatment in Taiwan colorectal cancer. Anti Cancer Drugs 2015;26:888–93. https://doi.org/10.1097/cad.0000000000000261.Search in Google Scholar

57. Ramos-Esquivel, A, Chinchilla-Monge, R, Abbas, J, Valle, M. C677T and A1298C MTHFR gene polymorphisms and response to fluoropyrimidine-based chemotherapy in Mestizo patients with metastatic colorectal cancer. Pharmacogenetics Genom 2021;31:191–9. https://doi.org/10.1097/fpc.0000000000000440.Search in Google Scholar PubMed

58. Amstutz, U, Henricks, LM, Offer, SM, Barbarino, J, Schellens JHM, Swen, J, et al.. Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 2018;103:210–6. https://doi.org/10.1002/cpt.911. Search in Google Scholar PubMed PubMed Central

59. Lunenburg, CATC, van der Wouden, CH, Nijenhuis, M, Crommentuijn-van Rhenen, MH, de Boer-Veger, NJ, Buunk, AM, et al.. Dutch pharmacogenetics working group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines. Eur J Hum Genet 2020;28:508–17. https://doi.org/10.1038/s41431-019-0540-0.Search in Google Scholar PubMed PubMed Central

60. Sun, N, Sun, X, Chen, B, Cheng, H, Feng, J, Cheng, L, et al.. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2010;65:437–46. https://doi.org/10.1007/s00280-009-1046-1.Search in Google Scholar PubMed PubMed Central

61. Ke, HG, Li, J, Shen, Y, You, QS, Yan, Y, Dong, HX, et al.. Prognostic significance of GSTP1, XRCC1 and XRCC3 polymorphisms in non-small cell lung cancer patients. Asian Pac J Cancer Prev APJCP 2012;13:4413–6. https://doi.org/10.7314/apjcp.2012.13.9.4413.Search in Google Scholar PubMed

62. Oh, J, Ban, MR, Miskie, BA, Pollex, RL, Hegele, RA. Genetic determinants of statin intolerance. Lipids Health Dis 2007;6:7. https://doi.org/10.1186/1476-511x-6-7.Search in Google Scholar

63. Ruaño, G, Windemuth, A, Wu, AH, Kane, JP, Malloy, MJ, Pullinger, CR, et al.. Mechanisms of statin-induced myalgia assessed by physiogenomic associations. Atherosclerosis 2011;218:451–6. https://doi.org/10.1016/j.atherosclerosis.2011.07.007.Search in Google Scholar PubMed PubMed Central

64. International Trade Administration. U.S. Department of Commerce, Bangladesh-Country Commercial Guide: Health and Pharmaceuticals. Available from: https://www.trade.gov/country-commercial-guides/bangladesh-healthcare-and-pharmaceuticals [Accessed 27 Jun 2022].Search in Google Scholar

Supplementary Material

This article contains supplementary material (https://doi.org/10.1515/dmpt-2022-0194).

Received: 2022-11-27
Accepted: 2023-01-25
Published Online: 2023-03-01

© 2023 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Pharmacogenetics and ethnicity: “Dr. José María Cantú” award announcement
  4. Review
  5. A review of pharmacogenetic studies in the Bangladeshi population
  6. Original Articles
  7. The ANKK1/DRD2 gene TaqIA polymorphism (rs1800497) is associated with the severity of extrapyramidal side effects of haloperidol treatment in CYP2D6 extensive metabolizers with schizophrenia spectrum disorders
  8. Effect of CYP2D6*4, CYP2D6*10 polymorphisms on the safety of treatment with timolol maleate in patients with glaucoma
  9. Actionable mutations in non-small cell lung cancer in patients at hospital de Especialidades Eugenio Espejo, Ecuador 2017–2020
  10. Impact of FCGR2A R131H, FCGR3A F158V and FCGR3B NA1/NA2 polymorphisms on response to Fc-containing TNF inhibitors in Tunisian rheumatoid arthritis patients
  11. CYP2C9 gene polymorphisms influence on antihypertensive effectiveness and hypouricemic effect of losartan among patients with arterial hypertension: an observational study
  12. Assessing the efficacy and safety of Unani pharmacopoeial formulations in dermatophytosis (quba) – a randomized controlled trial
  13. Quantitative assessment of antioxidant potential of selected homeopathic preparations in clinical practice
  14. Influence of EPHX1 c.337 T>C and UGT2B7*2 genetic polymorphisms on the requirement of carbamazepine maintenance dose in persons with epilepsy (PWE) of Southern part of India: a cross-sectional genetic association study
  15. Cathine and cathinone disposition kinetics and neurotransmitter profile in several organs of rats exposed to a single dose of Catha edulis (Vahl) Forssk. ex Endl. extract
https://doi.org/10.1515/dmpt-2022-0194
Keywords for this article
Bangladesh; implementation; pharmacogenetics; precision medicine

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Pharmacogenetics and ethnicity: “Dr. José María Cantú” award announcement
  4. Review
  5. A review of pharmacogenetic studies in the Bangladeshi population
  6. Original Articles
  7. The ANKK1/DRD2 gene TaqIA polymorphism (rs1800497) is associated with the severity of extrapyramidal side effects of haloperidol treatment in CYP2D6 extensive metabolizers with schizophrenia spectrum disorders
  8. Effect of CYP2D6*4, CYP2D6*10 polymorphisms on the safety of treatment with timolol maleate in patients with glaucoma
  9. Actionable mutations in non-small cell lung cancer in patients at hospital de Especialidades Eugenio Espejo, Ecuador 2017–2020
  10. Impact of FCGR2A R131H, FCGR3A F158V and FCGR3B NA1/NA2 polymorphisms on response to Fc-containing TNF inhibitors in Tunisian rheumatoid arthritis patients
  11. CYP2C9 gene polymorphisms influence on antihypertensive effectiveness and hypouricemic effect of losartan among patients with arterial hypertension: an observational study
  12. Assessing the efficacy and safety of Unani pharmacopoeial formulations in dermatophytosis (quba) – a randomized controlled trial
  13. Quantitative assessment of antioxidant potential of selected homeopathic preparations in clinical practice
  14. Influence of EPHX1 c.337 T>C and UGT2B7*2 genetic polymorphisms on the requirement of carbamazepine maintenance dose in persons with epilepsy (PWE) of Southern part of India: a cross-sectional genetic association study
  15. Cathine and cathinone disposition kinetics and neurotransmitter profile in several organs of rats exposed to a single dose of Catha edulis (Vahl) Forssk. ex Endl. extract
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 8.11.2025 from https://www.degruyterbrill.com/document/doi/10.1515/dmpt-2022-0194/html?lang=en
Scroll to top button